glp-1 weight loss drugs competitive analysis Receptor Agonists Obesity Market Size, Trends, Growth Report 2032 Glucagon-like Peptide-1 (GLP-1) Agonists Market

Saxenda is a drug that is approved by the U.S

Treatment requires medical evaluation and prescription

As a result, clinicians increasingly recognize that cardiometabolic risk assessment must extend beyond simple weight measurements

With the right policies and pricing strategies, these treatments could become a cornerstone in combating obesity over the next decade.

They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)

Weight-loss drugs could help people who have had a heart attack avoid suffering potentially fatal complications afterwards, research has found